Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Ascendis Pharma AS (Ascendis Pharma) is a biopharmaceutical company focused on developing innovative therapies using its proprietary TransCon technology platform. The company's main activities involve the research and development of therapies aimed at addressing unmet medical needs, particularly in endocrinology and oncology. Its product pipeline includes TransCon hGH for pediatric growth hormone deficiency, adult Growth hormone deficiency and turner syndrome; TransCon PTH for adult hypoparathyroidism; TransCon CNP for achondroplasia and TransCon IL-2 β/γ for treating oncology. The company operates in Spain, France, Sweden, Switzerland, the US, the UK, Germany, Italy, and Denmark. Ascendis Pharma is headquartered in Hellerup, Denmark.
Headquarters
Denmark
Address
Tuborg Boulevard 12, Hellerup, 2900
Website
www.ascendispharma.com
Telephone
45 702 22244
No of Employees
1,189
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ASND (NASD)
Revenue (2024)
$812.5M
98%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
39.7%
(2024 vs 2023)
Market Cap*
$17.8B
Net Profit Margin (2024)
XYZ
69.5%
(2024 vs 2023)
* As of and is in US$
Ascendis Pharma AS premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | TransCon |
| Endocrinology Rare Diseases: | |
| TransCon hGH: Pediatric GHD (Growth Hormone Deficiency), Adult GHD (Growth Hormone Deficiency), Turner Syndrome | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In February, the company received authorization from Health Canada for Yorvipath (palopegteriparatide injection) for treating chronic hypoparathyroidism in adults. |
| 2026 | Regulatory Approval | In February, the company secured FDA approval for once-weekly YUVIWEL to boost growth in children with achondroplasia aged two and older. |
| 2025 | Regulatory Approval | In June, the company received acceptance from the US Food & Drug Administration for priority review of its new drug application for TransCon CNP (navepegritide) for the treatment of children with achondroplasia. |
Competitor Comparison
| Key Parameters | Ascendis Pharma AS | Zealand Pharma AS | OPKO Health Inc | Nektar Therapeutics | Serina Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | Denmark | Denmark | United States of America | United States of America | United States of America |
| City | Hellerup | Soeborg | Miami | San Francisco | Huntsville |
| State/Province | - | - | Florida | California | Alabama |
| No. of Employees | 1,189 | 544 | 2,275 | 63 | 13 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Albert Cha, M.D, Ph.D. | Chairman | Executive Board | 2021 | 53 |
| Jan Moller Mikkelsen | Chief Executive Officer; Director; President | Executive Board | 2007 | 66 |
| Scott T. Smith | Chief Financial Officer; Executive Vice President | Senior Management | 2023 | 52 |
| Michael Wolff Jensen | Chief Legal Officer; Executive Vice President | Senior Management | 2023 | 54 |
| Lotte Sonderbjerg | Chief Administrative Officer; Executive Vice President | Senior Management | 2023 | 64 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer